Nick Tschernia, MD
@NickTscherniaMD
Followers
297
Following
4K
Statuses
459
Doctor of Hematology/Oncology • Physician-Scientist Early Investigator at NIH • Tweets are my own. He/him #Immunotherapy #CellTherapy #Cancer
Washington, DC
Joined September 2020
@Dr_RaviMadan Great point, you'd probably anticipate a transient early debulking and could meter some of the effect out with a slightly later assessment. The real Q is synergy of adding low dose metronomic post-CAR balancing early depletion vs ⬇️ exhaustion & Sustained Treg / MDSC Suppression
1
0
1
RT @RahulBanerjeeMD: 1/ Sobering but important work in @NEJM by @MScordoMD @szusmani et al: fatal case of enteric T-cell lymphoma following…
0
53
0
RT @NatRevDrugDisc: Novel strategies to manage CAR-T cell toxicity This new Review discusses management of safety…
0
111
0
@VincentRK A concern is if this is the first of a larger plan to scrap the extramural system altogether. Page 462 of Project 2025, proposes getting rid of, or significantly reducing, centrally funded peer reviewed NIH grants. Replacing it with block state grants.
0
0
2
RT @Transplant_Doc: Outpatient Teclistamab step-up dosing (SUD) is safe and feasible. Among 57 patients, 18 developed CRS, mostly gr 1, and…
0
7
0
RT @JAMAOnc: Chimeric antigen receptor–T-cell (CAR-T) therapy has revolutionized the treatment of hematologic cancers. This review discusse…
0
21
0
RT @jitcancer: New #JITC article: Integrating binding affinity and tonic signaling enables a rational CAR design for augmented T cell funct…
0
2
0
RT @HeczeyLab: IL15 increases the expansion of CAR T cells and induces antitumor responses in patients with GPC3+ solid tumors (i.e. liver…
0
37
0
RT @jitcancer: New #JITC article: Comparison of CAR T-cell and bispecific antibody as third-line or later-line treatments for multiple myel…
0
5
0
RT @ASTCT_Journal: Prophylactic IL-6 receptor blockade with tocilizumab may reduce severe CRS in axi-cel for LBCL, but it comes with a caut…
0
30
0
RT @RahulBanerjeeMD: 1/ 🚨 Now in @BloodCancerJnl - our multicenter description of IEC-associated enterocolitis as a novel toxicity of CAR-T…
0
46
0
Celebrating the Dr. Steven Rosenberg's 50 Years @NCI_CCR_SB and the Past, Present, and Future of Cellular Immunotherapy. Highlighting challenges of the first gene transfer protocol. (And taking the hardest question of his career - from Ms. Rosenberg)
0
1
8
RT @ArndtVogel: Ponsegromab for the Treatment of Cancer Cachexia @NEJM 👉Ponsegromab = humanized monoclonal antibod…
0
25
0
RT @ChristianRolfo: @StoverLab @FoundationATCG @broadinstitute Very good point! Integration of liquid biopsy and RECIST criteria is a need…
0
8
0
RT @BLLPHD: Mega CAR T meta-analysis "Second primary malignancies after CAR T-cell therapy: A systematic review and meta-analysis of 5,517…
0
44
0